

## Special Issue

# Advances in ImmunoTherapy of Cancer

### Message from the Guest Editors

Cancer vaccines have emerged as a transformative approach in oncology, leveraging the immune system to target and eliminate malignant cells. Based on the deep understanding of tumor immunity and great improvements in biotechnology and artificial intelligence (AI), cancer vaccines have become increasingly prominent in cancer immunotherapies.

We are pleased to invite you to contribute to this Special Issue, *Advances in ImmunoTherapy of Cancer*, of the *Vaccines* journal, **aimed at reporting new advances in cancer vaccines and cancer immunotherapy, such as new cancer vaccines, new technology for cancer vaccine development, and the immunomechanism of cancer vaccines.**

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- immunomechanism of cancer vaccines
- mRNA-based cancer vaccines
- tumor neoantigens
- peptide-based vaccines
- adjuvant
- antigen finding and AI-driven antigen prediction
- combination therapies
- vaccine delivery

### Guest Editors

Prof. Dr. Li Ye

School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

Dr. Jiajun Fan

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China

### Deadline for manuscript submissions

31 May 2026



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/242724](https://mdpi.com/si/242724)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).